Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2024 report and make more profitable business decisions.
Hospital-acquired pneumonia (HAP) is defined as pneumonia acquired during a hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.
The Hospital Acquired Pneumonia (HAP) drugs in development market research report provide comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hospital Acquired Pneumonia (HAP) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 50 molecules, with 50 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hospital Acquired Pneumonia (HAP) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hospital Acquired Pneumonia (HAP) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hospital Acquired Pneumonia (HAP) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAbelZeta Inc
AiCuris Anti-infective Cures AG
Antabio SAS
Aridis Pharmaceuticals Inc
Bioversys AG
Clarametyx Biosciences Inc
ContraFect Corp
Eldec Pharmaceuticals Inc
Evopoint Bioscience Co Ltd
Evotec SE
F. Hoffmann-La Roche Ltd
GangaGen Biotechnologies Pvt Ltd
Genloci Biotechnology Inc
Glox Therapeutics Ltd
Helperby Therapeutics Group Ltd
Hoth Therapeutics Inc
La Jolla Pharmaceutical Company
MD Healthcare Inc
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Nosopharm SAS
Omnix Medical Ltd
Peptineo
Pfizer Inc
PHAXIAM Therapeutics SA
Phico Therapeutics Ltd
Pulmobiotics SL
Qilu Pharmaceutical Co Ltd
Revagenix Inc
SciClone Pharmaceuticals Holdings Ltd
Shanghai SIMR Biotech Co Ltd
Shionogi & Co Ltd
Spexis AG
Sumitomo Pharma Co Ltd
Swedish Orphan Biovitrum AB
Therapeutic Systems Research Laboratories Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
Zai Lab Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hospital Acquired Pneumonia (HAP) reports